Skip to main content

ACR20 Best Abstracts - Day 3

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 3 (#ACRbest).

  1. Obesity, high-positive CRP, poor functional status, and a smoking threshold of 30 pack-years as novel predictors of RA-ILD  Abstract #1198
  2. SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA. UPA 15mg or 30mg improved  PROs  vs. Placebo thru 24wks with both doses similar or better than adalimumab.  Abstract #1341
  3. MAS and secondary HLH -  Highlighting the use of neopterin in following disease course and CXCL9 in active disease.- large cohort of 82 pts ; IL-18  a potential marker for MAS. Abstract 1150
  4. Dr Joshua presents that citrulline-reactive B cells producing pathogenic ACPAs are present in the lungs of seropositive patients with arthralgia or early RA.  Supports lung as key site of initiation of RA.  Abstract #1445
  5. Study fo anakinra safety in 306 pts w/sJIA meeting ILAR criteria:  Adverse events were most common in fist 6 mos of Rx.   Amongst 56 SAEs, there were 13 infections (23.2%; IR 2.6/100 py) & 11 MAS episodes (19.6%; IR 2.2/100 py). No death or malignancy. No new safety signals. Abstract # 1155
  6. Tildrakizumab was well tolerated in PsA pts and achieved LDA and remission targets in 52 week study. #Abstract #1369  
  7. This study identified novel risk factors for RA-ILD:  Obesity, ⬆CRP(≥10mg/L), Poor function (MDHAQ ≥1), Higher education,  30 pk-yr smoking hx; all associated with ⬆ RA-ILD risk.  Abstract #1198




If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject